The study looked at women with uterine fibroids and compared two treatments: microwave ablation alone versus microwave ablation plus a hormone drug (GnRH agonist). Adding the hormone drug helped shrink the fibroids more, reduced symptoms and pain, and lowered side‑effects and recurrence, but the research is specific to a medical condition and not about general health, longevity, or performance.

Uterine fibroids seriously affect patients' physical and mental health and clinical treatment currently faces certain challenges. This study analysed the efficacy and safety of gonadotropin-releasing hormone agonist (GnRH-a) combined with ultrasound-guided percutaneous microwave ablation (UPMA) in the treatment of uterine fibroids. In a retrospective study, 120 patients with uterine fibroids from Zhangye Second People's Hospital between March 2023 and December 2023 were divided into GA and GU groups, both groups were treated with UPMA and GnRH-a treatment was added to the GU group. Fibroid volume, fibroid shrinkage rates (FSR), symptom severity score (SSS), sex hormone levels, serum indicator levels and clinical efficacy were mainly assessed. Secondary outcomes included pain scores, uterine fibroid-relative symptom and health-related qualities of life scores (UFS-HRQL), complication profiles, recurrence rates and adverse reaction incidence. After treatment, both groups had better indicators than pre-treatment (P<0.05). The FSR, serum indicator levels, clinical efficacy and UFS-HRQL scores in the GU group were superior to the GA group and fibroids volume, SSS, sex hormone, pain scores, complication conditions, recurrence rate and adverse reaction incidences were markedly below GA group (P<0.05). This method has remarkable efficacy, can effectively reduce clinical symptoms and is worth promoting its use in clinical practice.